|Zygomycosis in the immunocompromised patient: a case report.|
|PMID: 16918059 Owner: NLM Status: MEDLINE|
|Zygomycosis is a highly aggressive infection observed in immunocompromised patients, such as those with haematological malignancies. The sites most frequently involved are the sinuses and the lungs. New diagnostic tools and new antifungal treatments are essential in order to diagnose early and treat efficiently infections due to moulds. We report a case of sinusitis due to Absidia corymbifera occurring during chemotherapy-induced bone marrow aplasia in a patient with acute leukaemia. The sinusitis was successfully treated with AmBisome, and surgical debridement.|
|Aspasia Georgala; Marc Vekemans; Mireille Husson; Nathalie Meuleman; Hugues Beguin; Nicole Nolard; Mickael Aoun|
Related Documents :
|11227849 - Esophageal candidiasis in non-immune suppressed patients in a semi-urban town, southern...
2005939 - Detection of circulating candida enolase by immunoassay in patients with cancer and inv...
11112669 - Travel-associated burkholderia pseudomallei infection (melioidosis) in a patient with c...
6990879 - Proteus vulgaris agglutination by cystic fibrosis sera.
12127859 - Recent progress in the diagnosis of fungal infections in the immunocompromised host.
11545239 - Post-antifungal effect of polyene, azole and dna-analogue agents against oral candida a...
24326809 - Effect of the number of portal area on modified histological activity index of viral he...
8276349 - Hepatitis c virus genotypes: an investigation of type-specific differences in geographi...
9815239 - Variability in repeated consecutive measurements of plasma human immunodeficiency virus...
|Type: Case Reports; Journal Article|
|Title: Acta bio-medica : Atenei Parmensis Volume: 77 Suppl 2 ISSN: 0392-4203 ISO Abbreviation: - Publication Date: 2006|
|Created Date: 2006-08-21 Completed Date: 2006-12-04 Revised Date: 2008-09-25|
Medline Journal Info:
|Nlm Unique ID: 101295064 Medline TA: Acta Biomed Country: Italy|
|Languages: eng Pagination: 5-9 Citation Subset: IM|
|Infectious Disease Department, Jules Bordet Institute, Brussels, Belgium. firstname.lastname@example.org|
|APA/MLA Format Download EndNote Download BibTex|
isolation & purification*
Amphotericin B / administration & dosage, therapeutic use*
Amsacrine / administration & dosage
Antifungal Agents / administration & dosage, therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Combined Modality Therapy
Cytarabine / administration & dosage
Daunorubicin / administration & dosage
Drug Resistance, Fungal
Drug Resistance, Neoplasm
Etoposide / administration & dosage
Fluconazole / therapeutic use
Leukemia / complications, drug therapy
Mucormycosis / drug therapy*, microbiology, surgery
Sinusitis / drug therapy*, microbiology, radiography, surgery
Tomography, X-Ray Computed
|0/Aerosols; 0/Antifungal Agents; 0/Liposomes; 0/liposomal amphotericin B; 1397-89-3/Amphotericin B; 147-94-4/Cytarabine; 20830-81-3/Daunorubicin; 33419-42-0/Etoposide; 51264-14-3/Amsacrine; 86386-73-4/Fluconazole|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A case of pelvic bone hydatidosis--diagnosis and treatment.
Next Document: Disseminated invasive aspergillosis in a patient with acute leukaemia.